Management of pneumonitis post-concurrent chemoradiation and immunotherapy in patients with advanced lung cancer: Case report and litterature review
Nội dung chính của bài viết
Tóm tắt
Immune-related pneumonitis is a rare but serious complication in patients with non-small cell lung cancer (NSCLC) treated with durvalumab after concurrent chemoradiotherapy (CRT). We encountered a 61-year-old male with stage III non-small cell lung cancer (NSCLC) receiving concurrent chemoradiotherapy followed by durvalumab maintenance therapy. After 1 cycle of durvalumab treatment, he developed progressive dyspnea, dry cough, and low-grade fever. Chest CT scans revealed diffuse ground-glass opacities in both lungs, indicative of immune-related pneumonitis. Durvalumab was discontinued, and the patient was treated with high-dose corticosteroids and antibiotics. After one month, he fully recovered. Durvalumab was cautiously resumed under close monitoring without recurrence of pneumonitis. Conclusion: Early identification and management of immune-related pneumonitis are essential in NSCLC patients receiving durvalumab. Reintroducing durvalumab after recovery may be safe with vigilant monitoring.
Chi tiết bài viết
Từ khóa
Non-small cell lung cancer, durvalumab, immune-related pneumonitis, chemoradiotherapy, immunotherapy rechallenge
Tài liệu tham khảo
2. Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of Oncology. 2017;28:iv1-iv21. doi:10.1093/annonc/mdx222
3. Sj A, A V, D D, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. The New England journal of medicine. 2017;377(20). doi:10.1056/NEJMoa1709937
4. Antonia SJ, Villegas A, Daniel D, et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018;379(24):2342-2350. doi:10.1056/NEJMoa1809697
5. Palma DA, Senan S, Tsujino K, et al. Predicting Radiation Pneumonitis After Chemoradiation Therapy for Lung Cancer: An International Individual Patient Data Meta-analysis. International Journal of Radiation Oncology, Biology, Physics. 2013;85(2):444-450. doi:10.1016/j.ijrobp.2012.04.043
6. Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. Journal of Thoracic Oncology. 2016;11(1):39-51. doi:10.1016/j.jtho.2015.09.009
7. Wang H, Guo X, Zhou J, et al. Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis. Thoracic Cancer. 2019;11(1):191. doi:10.1111/1759-7714.13240
8. Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018;378(2):158-168. doi:10.1056/NEJMra1703481
9. Rahi MS, Parekh J, Pednekar P, et al. Radiation-Induced Lung Injury-Current Perspectives and Management. Clin Pract. 2021;11(3):410-429. doi:10.3390/clinpract11030056
10. Arroyo-Hernández M, Maldonado F, Lozano-Ruiz F, et al. Radiation-induced lung injury: current evidence. BMC Pulmonary Medicine. 2021;21(1):9. doi:10.1186/s12890-020-01376-4
11. Thomas R, Chen YH, Hatabu H, et al. Radiographic Patterns of Symptomatic Radiation Pneumonitis in Lung Cancer Patients: Imaging Predictors for Clinical Severity and Outcome. Lung Cancer. 2020;145:132-139. doi:10.1016/j.lungcan.2020.03.023
12. Jung W, Shim SS, Kim K. CT findings of acute radiation-induced pneumonitis in breast cancer. Br J Radiol. 2021;94(1124):20200997. doi:10.1259/bjr.20200997
13. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714-1768. doi:10.1200/JCO.2017.77.6385
14. Schneider BJ, Naidoo J, Santomasso BD, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021;39(36):4073-4126. doi:10.1200/JCO.21.01440
15. Santini FC, Rizvi H, Plodkowski AJ, et al. Safety and Efficacy of Retreating with Immunotherapy After Immune-Related Adverse Events in Patients with NSCLC. Cancer Immunol Res. 2018;6(9):1093-1099. doi:10.1158/2326-6066.CIR-17-0755
16. Allouchery M, Beuvon C, Pérault-Pochat MC, et al. Safety of Immune Checkpoint Inhibitor Resumption after Interruption for Immune-Related Adverse Events, a Narrative Review. Cancers. 2022;14(4). doi:10.3390/cancers14040955